HIMS

$24.98

Market ClosedAs of Mar 17, 8:00 PM UTC

Hims & Hers Health, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$24.98
Potential Downside
52.9%
Whystock Fair Value$11.75
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and int...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.69B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
48.98
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
25.23%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.51

Recent News

Motley Fool
Mar 17, 2026

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Wall Street Journal
Mar 17, 2026

Health Care Roundup: Market Talk

1515 ET – For obesity-drug makers, success will be defined by price rather than product differentiation, HSBC analysts say. Pricing competition is set to heat up between Eli Lilly and Novo Nordisk, the analysts say. Lilly’s current guidance — which is more optimistic than Novo Nordisk’s — implies it will get a surge in GLP-1 demand when it cuts prices.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 17, 2026

Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus

Novo Nordisk (CPSE:NOVO B) has entered a partnership with Hims & Hers to provide access to its FDA approved GLP-1 obesity and diabetes drugs, Ozempic and Wegovy, through telehealth channels. The agreement resolves a public legal dispute between the two companies and could influence how patients in the United States access branded GLP-1 treatments. The announcement comes at a time of increasing competition and the rise of copycat medications in the obesity treatment space. For investors...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 17, 2026

Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know

Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal entails access to Novo’s GLP-1 drugs, Ozempic and Wegovy, at Hims & Hers’ platform. ​Management noted that as part of this […]

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Mar 16, 2026

Hims And Hers Health Pushes Into Complex Care And Global Growth

Hims & Hers Health (NYSE:HIMS) is expanding into complex health categories such as cancer care, longevity treatments, and at-home lab testing. The company is pursuing these areas through acquisitions that aim to bring more of the care journey onto its own platform. Hims & Hers Health is also ramping up international expansion, moving beyond its core US telehealth base. The shift marks a move away from a primary focus on telehealth visits and weight loss drugs toward a broader digital health...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.